Not long after arriving at the George Washington University (GW) School of Medicine and Health Sciences, Sharad Goyal, MD, professor of radiology, is forging a path for himself in the field of radiation oncology.
Goyal was recently selected to be a member of the NRG Oncology Developmental Therapeutics Radiation Therapy Subcommittee where he will spend the next two years working with members of the committee and the National Institutes of Health to bring new drugs to clinical trials.
“I think this is a great opportunity to give GW a place at the table with respect to working in a cooperative group,” said Goyal. “It raises the profile of not only radiation oncology, but also GW and the GW Cancer Center.”
NRG Oncology is one of three major cooperative groups that run clinical trials across the United States. There are subcommittees that cover each type of cancer that NRG Oncology works on. The Developmental Therapeutics Radiation Therapy Subcommittee helps to determine what molecular pathways or drug combinations may be more interesting or feasible in treatments. It also determines what types of tumors may benefit from those drug combinations with radiation therapy.
While on the subcommittee, Goyal will participate in bimonthly conference calls and annual meetings.
“Personally, I enjoy working in these types of situations and being part of a group that could help advance the field of cancer therapeutics,” Goyal said. “I look forward to learning more about the process of getting clinical trials started and seeing them to fruition. I hope to use some of that knowledge to start clinical trials institutionally and continue my involvement with the NRG.”
More information about NRG Oncology
